Nisa Investment Advisors LLC Purchases 68,900 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Nisa Investment Advisors LLC boosted its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 1,129.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 75,000 shares of the biopharmaceutical company's stock after acquiring an additional 68,900 shares during the period. Nisa Investment Advisors LLC's holdings in Royalty Pharma were worth $2,107,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Allworth Financial LP increased its position in Royalty Pharma by 89.8% during the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 451 shares during the period. EverSource Wealth Advisors LLC increased its position in Royalty Pharma by 112.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 531 shares during the period. Captrust Financial Advisors increased its position in Royalty Pharma by 210.8% during the 2nd quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 546 shares during the period. Acadian Asset Management LLC acquired a new position in Royalty Pharma during the 1st quarter worth approximately $113,000. Finally, CWM LLC increased its position in Royalty Pharma by 75.9% during the 3rd quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company's stock worth $130,000 after purchasing an additional 2,064 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Thursday. Bank of America decreased their price target on Royalty Pharma from $40.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday. The Goldman Sachs Group decreased their price target on Royalty Pharma from $56.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. reduced their target price on Royalty Pharma from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Royalty Pharma has an average rating of "Buy" and a consensus target price of $46.75.

Royalty Pharma Trading Down 2.9 %

Shares of RPRX traded down $0.83 during trading hours on Friday, hitting $28.22. The stock had a trading volume of 3,161,444 shares, compared to its average volume of 2,270,679. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90. The firm has a market cap of $16.86 billion, a P/E ratio of 14.93, a P/E/G ratio of 0.81 and a beta of 0.45. The company's fifty day simple moving average is $29.89 and its 200 day simple moving average is $28.50. Royalty Pharma plc has a 12-month low of $25.92 and a 12-month high of $36.67.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.12. The business had revenue of $736.00 million for the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. Equities research analysts forecast that Royalty Pharma plc will post 3.89 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, February 16th were given a $0.21 dividend. The ex-dividend date was Thursday, February 15th. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.20. This represents a $0.84 annualized dividend and a yield of 2.98%. Royalty Pharma's dividend payout ratio (DPR) is 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.